Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+breast cancer cells

被引:9
|
作者
Murad, Rabi [1 ]
Avanes, Arabo [2 ]
Ma, Xinyi [1 ]
Geng, Shuhui [2 ]
Mortazavi, Ali [1 ]
Momand, Jamil [2 ]
机构
[1] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92617 USA
[2] Calif State Univ Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90032 USA
基金
美国国家卫生研究院;
关键词
breast cancer; Herceptin; trastuzumab; drug resistance; FoxJ3; Sox2; ATAC-seq; differentially expressed genes; METASTATIC BREAST-CANCER; T-DARPP; EXPRESSION; RECEPTOR; CHEMOTHERAPY; WOMEN; LINES; SEQ;
D O I
10.1016/j.gene.2021.145808
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We set out to uncover transcriptome and chromatin landscape changes that occur in HER2 + breast cancer (BC) cells upon acquiring resistance to trastuzumab. RNA-seq analysis was applied to two independently-derived BC cell lines with acquired resistance to trastuzumab (SKBr3.HerR and BT-474HerR) and their parental drugsensitive cell lines (SKBr3 and BT-474). Chromatin landscape analysis indicated that the most significant increase in accessibility in resistant cells occurs in PPP1R1B within a segment spanning introns 1b through intron 3. Footprint analysis of this segment revealed that FoxJ3 (within intron 2) and Pou5A1/Sox2 (within inton 3) transcription factor motifs are protected in resistant cells. Overall, 344 shared genes were upregulated in both resistant cell lines relative to their parental counterparts and 453 shared genes were downregulated in both resistant cell lines relative to their parental counterparts. In resistant cells, genes associated with autophagy and mitochondria organization are upregulated and genes associated with ribosome assembly and cell cycle are downregulated relative to parental cells. The five top upregulated genes in drug-resistant breast cancer cells are APOD, AZGP1, ETV5, ALPP, and PPP1R1B. This is the first report of increased chromatin accessibility within PPP1R1B associated with its t-Darpp transcript increase, and points to a possible mechanism for its activation in trastuzumab-resistant cells.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] The promise of miR-205 in HER2+breast cancer: predicting response to Trastuzumab and overcoming resistance
    Piovan, Claudia
    D'Ippolito, Elvira
    Plantamura, Ilaria
    Casalini, Patrizia
    Tagliabue, Elda
    Lorio, Marilena V.
    CANCER RESEARCH, 2016, 76
  • [22] Delineating the mechanisms of resistance to panHER inhibitors in HER2+breast cancer cells
    Kutuk, O.
    Basaga, H.
    Ozmay, Y.
    Karakas, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+breast cancer cells
    DiScala, Molly
    Najor, Matthew S.
    Yung, Timothy
    Morgan, Deri
    Abukhdeir, Abde M.
    Cobleigh, Melody A.
    PLOS ONE, 2020, 15 (06):
  • [24] Effect of trastuzumab on the antiproliferative effects of PI3K inhibitors in HER2+breast cancer cells with de novo resistance to trastuzumab.
    Espin, Estefania
    Alejandro Perez-Fidalgo, Jose
    Tormo, Eduardo
    Pineda, Begona
    Miguel Cejalvo, Juan
    Sabbaghi, MohammadA
    Alonso, Elisa
    Rovira, Ana
    Rojo, Federico
    Albanell, Joan
    Bermejo, Begona
    Burgues, Octavio
    Eroles, Pilar
    Lluch, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Factors associated with non use of adjuvant trastuzumab in older patients with HER2+breast cancer.
    Luis, Ines Vaz
    Lin, Nancy U.
    Keating, Nancy Lynn
    Barry, William Thomas
    Lii, Joyce
    Burstein, Harold J.
    Winer, Eric P.
    Freedman, Rachel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] HER2+breast cancer
    Hicks, David G.
    Kulkarni, Swati
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (02) : 263 - 273
  • [27] Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells
    Mao, Yan
    Zhang, Yuzi
    Qu, Qing
    Zhao, Meizhong
    Lou, Ying
    Liu, Junjun
    Huang, Ou
    Chen, Xiaosong
    Wu, Jiayi
    Shen, Kunwei
    MOLECULAR BIOSYSTEMS, 2015, 11 (04) : 1029 - 1040
  • [28] Adjuvant trastuzumab and vinorelbine for early-stage HER2+breast cancer
    McLaughlin, Shannon
    Nakajima, Erika
    Bar, Yael
    Hutchinson, Jennifer A. A.
    Shin, Jennifer
    Moy, Beverly
    Isakoff, Steven J. J.
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura M. M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [29] Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+Breast Cancer
    Song, Patrick N.
    Mansur, Ameer
    Lu, Yun
    Della Manna, Deborah
    Burns, Andrew
    Samuel, Sharon
    Heinzman, Katherine
    Lapi, Suzanne E.
    Yang, Eddy S.
    Sorace, Anna G.
    CANCERS, 2022, 14 (04)
  • [30] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)